AIM - Dosing underway in AIM Immunotech's long hauler part of ampligen COVID-19 trial

AIM ImmunoTech ([[AIM]] +0.5%) has dosed the first patient in the "Long Hauler" portion of its active AMP-511 Expanded Access Program, evaluating Ampligen in COVID-19 patients.The Ampligen EAP protocol is authorized at any one time to enroll up to 100 active Chronic Fatigue Syndrome trial participants, 20 of whom may be Long Haulers. All study subjects will receive the same Ampligen treatments.Ampligen is AIM's TLR3 agonist immune-system modulator. It is approved in Argentina as the world's first therapy for severe Chronic Fatigue Syndrome and the company says it is the only late-stage drug in the U.S. development pipeline for ME/CFS.In December, AIM won Institutional Review Board's green signal to commence enrollment in post-COVID-19 "Long Hauler" portion of the program.

For further details see:

Dosing underway in AIM Immunotech's "long hauler" part of ampligen COVID-19 trial